Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Carcinoma, Non-Small Cell Lung
Clinical trial register · United Kingdom · industry-sponsored

Carcinoma, Non-Small Cell Lung Trials in the UK, 2026

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a UK site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full UK registry across all sponsors is far larger. UK studies may also be registered separately on ISRCTN.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 2868 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 15 Oct 2026, 03:15 UTC
2868
Studies in scope
industry-sponsored, all four open statuses
1384
Recruiting now
open to new participants
542
Lead sponsors
across recruiting studies
Top sites
London 26 Manchester 14 Sutton 11 Birmingham 6 Edinburgh 5
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Janssen Research & Development, LLC8 Seagen, a wholly owned subsidiary of Pfizer6 Eli Lilly and Company3 Merck Sharp & Dohme LLC3 Bristol-Myers Squibb2
Site city
London26 Manchester14 Sutton11 Birmingham6 Edinburgh5
All 39 cities
Target enrolment
to

Carcinoma, Non-Small Cell Lung trials in the UK

30 of 2868 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
UK sites
Start
Recruiting
Janssen Research & Development, LLC
Observational
380
Bath, Cardiff, Eastbourne, Guildford, Heath Town, London, Manchester, Sutton
2025-12-03
Recruiting
Bristol-Myers Squibb
Phase 2
182
Birmingham, London, Newcastle upon Tyne
2025-09-09
Recruiting
Pfizer
Phase 3
714
Truro, Sheffield, Southampton, Northwood, London, Taunton, Ipswich, Manchester
2025-07-23
Recruiting
Mirati Therapeutics Inc.
Phase 3
630
London, Birmingham, Guildford, Manchester
2025-04-24
Recruiting
AstraZeneca
Phase 3
830
Blackpool, Glasgow, Guildford, Hull, Northwood, Oxford
2025-04-10
Recruiting
Eli Lilly and Company
Phase 3
700
Birmingham, East Sussex, Huddersfield, London, Manchester, Torquay
2025-03-27
Recruiting
Janssen Research & Development, LLC
Phase 2
480
Greater London, Liverpool, London, Manchester, Sutton, Torquay
2024-12-16
Recruiting
Johnson & Johnson Enterprise Innovation Inc.
Phase 2
130
London
2024-12-06
Recruiting
Merck Sharp & Dohme LLC
Phase 3
680
Bristol, London, Nottingham, Leeds, Leicester, Manchester, Metropolitan Borough of Wirral, Portsmouth
2024-10-21
Active, closed
Seagen, a wholly owned subsidiary of Pfizer
Phase 3
762
London, Glasgow, Manchester, Sutton
2024-02-21
Recruiting
Eli Lilly and Company
Phase 3
1,264
Aberdeen, Dundee, Huddersfield, Leeds, Manchester, Northwood, Sheffield, Wolverhampton
2023-12-21
Recruiting
A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors
NCT06131840Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung, Stomach Neoplasms, Pancreatic Ductal Adenocarcinoma
DrugsLeucovorin·Adrucil·Oxaliplatin·Bevacizumab
Seagen, a wholly owned subsidiary of Pfizer
Phase 1
914
London, Edinburgh
2023-11-20
Active, closed
A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2
NCT06003231Carcinoma, Non-Small-Cell Lung, Ovarian Neoplasms, Endometrial Neoplasms, Head and Neck Neoplasms
DrugDisitamab Vedotin
Seagen, a wholly owned subsidiary of Pfizer
Phase 2
120
Sutton, London
2023-11-14
Active, closed
Janssen Research & Development, LLC
Phase 1/2
71
London, Newcastle, Sutton
2023-05-18
Active, closed
Merck Sharp & Dohme LLC
Phase 3
614
Leicester, London, Metropolitan Borough of Wirral
2023-02-06
Active, closed
Janssen Research & Development, LLC
Phase 1/2
57
London, Newcastle upon Tyne, Sutton
2022-12-13
Recruiting
Janssen Research & Development, LLC
Phase 2
520
Cheltenham, Devon, Edinburgh, Leicester, London, Nottingham, Portsmouth
2022-11-11
Recruiting
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
NCT05208762Carcinoma, Non-Small-Cell Lung, Squamous Cell Carcinoma of the Head and Neck, Esophageal Squamous Cell Carcinoma, Triple Negative Breast Neoplasms
DrugsPF-08046054·Keytruda·Pembrolizumab
Seagen, a wholly owned subsidiary of Pfizer
Phase 1
714
London, Sutton
2022-10-25
Active, closed
Eli Lilly and Company
Phase 3
152
London, Nottingham, Wolverhampton
2021-12-20
Active, closed
Janssen Research & Development, LLC
Phase 3
776
Cardiff, Edinburgh, London, Manchester
2021-11-17
Active, closed
Janssen Research & Development, LLC
Phase 3
308
Edinburgh, London, Sutton
2020-10-13
Active, closed
Janssen Research & Development, LLC
Phase 3
1,074
Edinburgh, London, Manchester, Nottingham, Sutton
2020-09-30
Active, closed
Merck Sharp & Dohme LLC
Phase 3
870
Sheffield, London, London-Camden, Southampton, Leeds, Manchester
2020-07-06
Recruiting
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
NCT04389632Carcinoma, Non-Small Cell Lung, Squamous Cell Carcinoma of Head and Neck, HER2 Negative Breast Neoplasms, Esophageal Squamous Cell Carcinoma
DrugsSigvotatug vedotin·Keytruda·Cisplatin·Carboplatin
Seagen, a wholly owned subsidiary of Pfizer
Phase 1
1,006
Sutton, Birmingham, London
2020-06-08
Active, closed
Bristol-Myers Squibb
Phase 3
461
Taunton
2019-11-05
Active, closed
AstraZeneca
Phase 3
724
Birmingham, Leeds, London, Manchester
2019-03-06
Active, closed
Hoffmann-La Roche
Phase 3
257
London, Manchester
2018-08-16
Active, closed
Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors
NCT03485209Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung, Exocrine Pancreatic Cancer, Carcinoma, Squamous Cell of Head and Neck
DrugsTisotumab Vedotin·Tivdak·Keytruda·Cisplatin
Seagen, a wholly owned subsidiary of Pfizer
Phase 2
350
London, Sutton
2018-06-25
Active, closed
Pfizer
Phase 3
296
Ipswich, Birmingham, Manchester
2017-04-27
Active, closed
A Study of TAK-788 in Adults With Non-Small Cell Lung Cancer
NCT02716116Carcinoma, Non-Small-Cell Lung
DrugMobocertinib
Takeda
Phase 1/2
334
London
2016-06-16
Rows per page Showing 1–30 of 30
1
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a UK investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 16 October 2026. https://priyalifescience.com/clinical-trials-uk/condition/carcinoma-non-small-cell-lung

Query this register directly
GET /api/trials?country=uk&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every industry-sponsored study on the registry that lists at least one investigative site in the UK and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 2,868 studies in total at the last sync on 15 Oct 2026, 03:15 UTC. Academic and other non-industry sponsors are out of scope by design. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 30 of those studies listing the condition Carcinoma, Non-Small Cell Lung.

How many Carcinoma, Non-Small Cell Lung trials are recruiting in the UK?

14 of the 30 studies on this page are recruiting new participants as of the 15 Oct 2026, 03:15 UTC sync. A further 0 have not yet opened recruitment, 16 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Carcinoma, Non-Small Cell Lung), 30 studies
PhaseStudiesRecruitingShare
Phase 317656.7%
Phase 26420%
Phase 13310%
Phase 1/23010%
Observational113.3%

Most active sponsors

Lead sponsors with the most studies (Carcinoma, Non-Small Cell Lung)
Lead sponsorStudiesRecruiting
Janssen Research & Development, LLC83
Seagen, a wholly owned subsidiary of Pfizer63
Eli Lilly and Company32
Merck Sharp & Dohme LLC31
AstraZeneca21
Bristol-Myers Squibb21
Pfizer21
Hoffmann-La Roche10
Johnson & Johnson Enterprise Innovation Inc.11
Mirati Therapeutics Inc.11
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the UK Pharma Salary Guide, or see the Ireland, EU and USA registers.